When did Edwards Lifesciences report Q4 2024 earnings?

Edwards Lifesciences (EW) reported Q4 2024 earnings on February 11, 2025 after market close.

What were Edwards Lifesciences's Q4 2024 revenue and EPS?

Edwards Lifesciences reported revenue of $1.4B and diluted EPS of $0.59 for Q4 2024.

Did Edwards Lifesciences beat estimates in Q4 2024?

Revenue beat the consensus estimate of $1.4B by $26.9M. EPS beat the consensus estimate of $0.55 by $0.04.

Where can I find Edwards Lifesciences's Q4 2024 SEC filings?

You can read the 10-K periodic report (0001099800-25-000005) directly on SEC EDGAR. The filing index links above go to sec.gov.

Edwards Lifesciences EW Q4 2024 Annual earnings

Reported February 11, 2025 · After market close

Revenue$1.4BBeat by $26.9M Diluted EPS$0.59Beat by $0.04

Revenue estimate$1.4B

EPS estimate$0.55

Next report

Jul 23, 2026 (In 1 week)

Revenue estimate$1.7B

EPS estimate$0.73

Financials

Q4 2024

Income statement

See full

Revenue$1.4B+9.4%

Gross profit$1.1B+7.7%

Operating income$312.6M-9.9%

Net income$385.6M+4.2%

EPS (diluted)$0.65+6.6%

Balance sheet

See full

Cash & equivalents$3.1B+166%

Total debt$700.0M+2.2%

Total equity$10.0B+50.4%

Total assets$13.1B+39.4%

Cash flow

See full

CapEx$49.8M-43.6%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$43.66B-5.6%

Enterprise value$41.3B-9.8%

P/E10.5×-22.5×

P/S8×-1.2×

Profitability

See full

Gross margin79.5%+1.2pp

Operating margin25.3%-1.9pp

Net margin76.7%+48.8pp

Returns & leverage

See full

Return on equity50.2%+27.6pp

Debt / equity0.1×0.0×

Current ratio4.2×+0.8×

Segments

By segment

See full

United States$812.9M+9.2%

Europe$343.7M+13.7%

Rest of World$143.3M+8.5%

Japan$85.9M-13.5%

By product

See full

Transcatheter Aortic Valve Replacement$1.0B+5.8%

Transcatheter Mitral and Tricuspid Therapies$105.1M+87.7%

Versus estimates

Revenue

Q1 2026$1.6BBeat by $51.8M Q4 2025$1.6BBeat by $22.7M Q3 2025$1.6BBeat by $55.3M Q2 2025$1.5BBeat by $44.2M Q1 2025$1.4BBeat by $12.2M

Q4 2024$1.4BBeat by $26.9M

Diluted EPS

Q1 2026$0.78Beat by $0.05 Q4 2025$0.58Miss by $0.04 Q3 2025$0.67Beat by $0.07 Q2 2025$0.67Beat by $0.05 Q1 2025$0.64Beat by $0.04

Q4 2024$0.59Beat by $0.04

Ask the moment Edwards Lifesciences reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Edwards Lifesciences report Q4 2024 earnings?: Edwards Lifesciences (EW) reported Q4 2024 earnings on February 11, 2025 after market close.
What were Edwards Lifesciences's Q4 2024 revenue and EPS?: Edwards Lifesciences reported revenue of $1.4B and diluted EPS of $0.59 for Q4 2024.
Did Edwards Lifesciences beat estimates in Q4 2024?: Revenue beat the consensus estimate of $1.4B by $26.9M. EPS beat the consensus estimate of $0.55 by $0.04.
Where can I find Edwards Lifesciences's Q4 2024 SEC filings?: You can read the 10-K periodic report (0001099800-25-000005) directly on SEC EDGAR. The filing index links above go to sec.gov.